St. Paul, Minnesota - Agitated Solutions, Inc. (ASI), a medical technology company developing innovative tools to enhance ultrasound imaging and diagnostic accuracy across multiple clinical applications, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its inaugural product, ASI-02.

St. Paul, Minnesota - The U.S. Food and Drug Administration (FDA) has cleared Agitated Solutions, Incorporated (ASI)’s Investigational New Drug (IND) application for its novel contrast agent, ASI-02, enabling the initiation of the company’s Phase 3 clinical trial.

St. Paul, Minnesota - Agitated Solutions, Incorporated (ASI) announced today that it has been issued a Medical Device License (MDL) from Health Canada for its innovative Orbis™ Microbubble Generator that simplifies and streamlines the process of saline agitation and delivery for cardiac bubble studies. Orbis is the first tool to automatically agitate the saline with uniform, small bubbles that endure longer for visibility.